Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Malignant Central Nervous System Neoplasm: early-phase trial registry
3 of 4 indexed Malignant Central Nervous System Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Malignant Central Nervous System Neoplasm: 4 US clinical trials tracked, 3 recruiting.
Malignant Central Nervous System Neoplasm is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Mayo Clinic, running 3 of these trials.
Enrollment posture brief
Registry condition malignant-central-nervous-system-neoplasm
OPEN 3 | RECR 75% | LATE 0 | EARLY 1 | RANK #4115 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Malignant Central Nervous System Neoplasm lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Malignant Central Nervous System Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Malignant Central Nervous System Neoplasm is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
M.D. Anderson Cancer Center
NCT00991094
Study of Human Brain-Gut Axis and Gut Microbiome in Patients With Brain Lesions - Repository for Neuroscience Research
Mayo Clinic
NCT06117930
Patient and Caregiver Priorities in Neuro-oncology Care
Mayo Clinic
NCT06676306
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
NCT04456140
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Malignant Central Nervous System Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Malignant Central Nervous System Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Malignant Central Nervous System Neoplasm page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Malignant Central Nervous System Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Mayo Clinic sponsors the most Malignant Central Nervous System Neoplasm trials on record, review their full trial history before evaluating a specific study. See Mayo Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Malignant Central Nervous System Neoplasm condition card totals 4 registered trials; most-linked intervention Non-Interventional Study; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.